Mechanism of action
Digoxin inhibits the sodium-potassium ATPase pump (Na-K-ATPase) on myocardial cell membranes. This inhibition leads to accumulation of intracellular sodium, which in turn reduces the activity of the sodium-calcium exchanger. The net result is increased intracellular calcium concentration, enhancing cardiac contractility through stronger actin-myosin interactions.
In the heart, digoxin produces positive inotropic effects by increasing the force of myocardial contraction. It also has important electrophysiologic effects: it increases vagal tone and slows conduction through the AV node, producing negative chronotropic and dromotropic effects. These properties make it useful for both increasing cardiac output in heart failure and controlling ventricular rate in atrial fibrillation.
The drug exhibits dose-dependent effects. At therapeutic doses, it improves cardiac output and reduces sympathetic activation. At toxic doses, it causes excessive intracellular calcium accumulation, leading to delayed afterdepolarizations and triggered arrhythmias. Digoxin has a narrow therapeutic index, with therapeutic levels typically between 0.5-2.0 ng/mL.
- Digoxin inhibits Na-K-ATPase, increasing intracellular calcium and cardiac contractility
- Classic toxicity triad: GI symptoms, visual changes (yellow-green vision), and arrhythmias
- Hypokalemia is the most important risk factor for digoxin toxicity
- Atrial tachycardia with AV block is pathognomonic for digoxin toxicity
- Digoxin is renally excreted; dose adjustment required in renal impairment
- Amiodarone increases digoxin levels by 70-100%; reduce digoxin dose by 50%
- Therapeutic range 0.5-2.0 ng/mL; for heart failure aim for 0.5-1.0 ng/mL
- Digoxin-specific antibody fragments (Digibind) are the antidote for life-threatening toxicity
Indications
Digoxin is FDA-approved for:
- Heart failure with reduced ejection fraction (HFrEF): Used as an adjunct to standard therapy (ACE inhibitors, beta-blockers, diuretics) to reduce hospitalizations and improve symptoms. It does not reduce mortality.
- Atrial fibrillation: For ventricular rate control, particularly in patients with concurrent heart failure or sedentary lifestyle. Less effective for rate control during exercise compared to beta-blockers or calcium channel blockers.
Digoxin is generally reserved as a second- or third-line agent in modern heart failure management. It may be particularly useful in patients who remain symptomatic despite optimal medical therapy, or in those who cannot tolerate beta-blockers. In atrial fibrillation, it is often used when other rate-control agents are contraindicated or ineffective.
Historically, digoxin was a first-line agent for heart failure, but contemporary guidelines favor neurohormonal antagonists (ACE inhibitors, ARBs, beta-blockers, aldosterone antagonists, SGLT2 inhibitors) that improve survival.
Pharmacokinetics
Absorption: Digoxin is 70-80% bioavailable after oral administration. Food does not significantly affect absorption, but high-fiber meals may reduce it slightly.
Distribution: The drug has a large volume of distribution (5-7 L/kg) and distributes extensively into skeletal and cardiac muscle. It does not distribute well into adipose tissue, so dosing should be based on lean body weight in obese patients. Digoxin crosses the placenta and enters breast milk.
Metabolism: Digoxin undergoes minimal hepatic metabolism. Approximately 16% is metabolized by intestinal bacteria and hepatic enzymes to inactive metabolites.
Excretion: The primary route of elimination is renal excretion of unchanged drug (60-80%). The elimination half-life is 36-48 hours in patients with normal renal function but can be prolonged to 4-6 days in renal impairment. Dosage adjustment is essential in kidney disease.
Steady state: Due to the long half-life, steady-state concentrations are reached in 5-7 days with daily dosing. Loading doses can be used to achieve therapeutic levels more rapidly when clinically necessary.
Digoxin levels are typically measured at steady state, with samples drawn at least 6-8 hours after the last dose to allow for distribution equilibrium.
Adverse effects
Digoxin toxicity is a critical clinical syndrome due to the drug's narrow therapeutic index. Toxicity can occur even at therapeutic doses in certain conditions.
Cardiac toxicity
- Arrhythmias: The most serious adverse effect. Virtually any arrhythmia can occur, but classic patterns include ventricular ectopy (PVCs, bigeminy), atrial tachycardia with AV block, junctional rhythms, and ventricular tachycardia. The combination of increased automaticity (due to calcium overload) and AV block (due to vagal effects) is highly suggestive of digoxin toxicity.
- Bradycardia and AV block: Excessive vagal stimulation can cause sinus bradycardia, first-degree AV block, or higher-degree blocks.
Gastrointestinal effects
- Anorexia, nausea, vomiting, and diarrhea are common early signs of toxicity
- These symptoms often precede cardiac manifestations
Neurological effects
- Confusion, delirium, and fatigue
- Visual disturbances: The classic presentation is yellow-green color vision (xanthopsia), blurred vision, or seeing halos around lights. This is a high-yield exam finding.
- Headache and dizziness
Factors predisposing to toxicity
- Hypokalemia: Most important risk factor. Low potassium enhances digoxin binding to Na-K-ATPase. Concurrent diuretic use is a common cause.
- Hypomagnesemia: Also increases toxicity risk
- Hypercalcemia: Exacerbates calcium-mediated toxicity
- Renal impairment: Decreases clearance
- Hypothyroidism: Reduces digoxin clearance
- Drug interactions: Especially with amiodarone, verapamil, quinidine, and others
- Advanced age: Reduced renal function and lean body mass
Treatment of toxicity
For significant toxicity with life-threatening arrhythmias, digoxin-specific antibody fragments (Digibind or DigiFab) are the definitive treatment. Supportive care includes correcting electrolyte abnormalities (especially potassium), atropine for bradycardia, and avoiding calcium administration (which can worsen arrhythmias). Cardioversion should be used cautiously as it can trigger ventricular fibrillation in digoxin toxicity.
Contraindications and warnings
Absolute contraindications:
- Ventricular fibrillation
- Known hypersensitivity to digoxin or other cardiac glycosides
- Ventricular tachycardia (unless due to heart failure and other treatments have failed)
Relative contraindications and warnings:
- Accessory pathway syndromes (Wolff-Parkinson-White): Digoxin can shorten the refractory period of the accessory pathway, potentially leading to rapid ventricular response and ventricular fibrillation during atrial fibrillation. This is an absolute contraindication in some guidelines.
- Hypertrophic cardiomyopathy: Increased contractility can worsen outflow obstruction
- Restrictive cardiomyopathy: May be less effective and potentially harmful
- Acute myocardial infarction: Use with caution in the acute phase
- Renal impairment: Requires dose reduction and careful monitoring
- Electrolyte disturbances: Correct hypokalemia, hypomagnesemia, and hypercalcemia before initiating therapy
- Sick sinus syndrome or AV block: Risk of worsening conduction abnormalities
Pregnancy and lactation: Pregnancy category C. Digoxin crosses the placenta but is generally considered safe when needed for maternal heart failure or arrhythmias. Maternal and fetal levels should be monitored. The drug enters breast milk but is usually compatible with breastfeeding at therapeutic maternal doses.
Elderly patients: Require lower doses due to decreased renal function and reduced lean body mass. More susceptible to toxicity.
Drug interactions
Digoxin has numerous clinically significant drug interactions due to its narrow therapeutic index and renal elimination.
Interactions increasing digoxin levels
- Amiodarone: Increases digoxin levels by 70-100% by inhibiting P-glycoprotein. Reduce digoxin dose by 50% when starting amiodarone.
- Verapamil and diltiazem: Increase levels by 50-75%
- Quinidine: Doubles digoxin levels by reducing renal and non-renal clearance
- Macrolide antibiotics (erythromycin, clarithromycin): Increase levels by killing gut bacteria that metabolize digoxin
- Propafenone and dronedarone: Significant increases in digoxin levels
- Spironolactone: May increase levels and interfere with digoxin assays
- Loop and thiazide diuretics: Do not directly increase digoxin levels but cause hypokalemia, which enhances toxicity
Interactions decreasing digoxin levels
- Antacids and kaolin-pectin: Reduce absorption; separate dosing by 2 hours
- Cholestyramine and colestipol: Bind digoxin in the gut
- Rifampin: Induces P-glycoprotein, reducing digoxin levels
- St. John's wort: Induces P-glycoprotein
- Metoclopramide: May reduce absorption
Pharmacodynamic interactions
- Beta-blockers and calcium channel blockers: Additive effects on AV node conduction; risk of bradycardia and heart block
- Succinylcholine: Risk of arrhythmias due to acute potassium shifts
- Sympathomimetics: May increase risk of arrhythmias
Clinical approach: When starting or stopping interacting drugs, monitor digoxin levels and clinical status closely. Empiric dose adjustments are often needed with known major interactions like amiodarone.
Clinical pearls
- Therapeutic drug monitoring: Target therapeutic range is 0.5-2.0 ng/mL, but for heart failure, lower levels (0.5-1.0 ng/mL) are associated with better outcomes and less toxicity. For atrial fibrillation rate control, levels up to 2.0 ng/mL may be needed.
- Hypokalemia is the most important modifiable risk factor for digoxin toxicity. Always check and correct potassium before and during digoxin therapy, especially in patients on diuretics.
- The combination of atrial tachycardia with AV block is pathognomonic for digoxin toxicity. This occurs because digoxin increases atrial automaticity while simultaneously increasing vagal tone at the AV node.
- Do not use calcium to treat hyperkalemia in digoxin-toxic patients, as it can precipitate fatal arrhythmias. Use other methods like insulin-glucose, beta-agonists, or dialysis.
- Cardioversion in digoxin toxicity should be performed at lower energy levels (start at 10-20 J) if absolutely necessary, as standard energies can precipitate ventricular fibrillation.
- Routine digoxin levels are not necessary in stable patients. Check levels when toxicity is suspected, renal function changes, interacting drugs are added, or symptoms develop.
- In atrial fibrillation, digoxin is less effective for rate control during exercise compared to beta-blockers or calcium channel blockers. It works best in sedentary patients or those with concurrent heart failure.
- Digoxin does not reduce mortality in heart failure, but it does reduce hospitalizations and improve symptoms. This was demonstrated in the landmark DIG trial.
- Loading doses should be divided and given over 24 hours (e.g., 50% initially, 25% at 6-8 hours, 25% at 12-16 hours) to allow for distribution and assessment of response.
- In acute digoxin toxicity from intentional overdose, activated charcoal can be used if the patient presents within 1 hour. For serious toxicity, calculate the number of vials of digoxin-specific antibody needed based on ingested amount or serum level.
DIGOXIN toxicity — GI symptoms first, then Yellow-green vision, then Arrhythmias (any type); remember "Dig toxicity needs LOW K" (hypokalemia worsens toxicity)
Practice questions
1. A 72-year-old man with chronic systolic heart failure on furosemide and digoxin presents with nausea, confusion, and palpitations. ECG shows frequent premature ventricular contractions and a junctional rhythm. Laboratory studies show: Na 138 mEq/L, K 2.9 mEq/L, Mg 1.4 mg/dL, digoxin level 2.8 ng/mL. Which of the following is the most important initial step in management?
2. A 65-year-old woman with atrial fibrillation and heart failure with reduced ejection fraction is started on digoxin. Two weeks later, she is prescribed amiodarone for rhythm control. What adjustment should be made to her digoxin regimen?
3. A 58-year-old man with newly diagnosed atrial fibrillation and Wolff-Parkinson-White syndrome is seen in clinic. His ventricular rate is 110-120 bpm at rest. Which medication should be avoided for rate control in this patient?
Frequently asked questions
How does digoxin work?
Digoxin inhibits the sodium-potassium ATPase pump in cardiac myocytes, leading to increased intracellular sodium and subsequently increased intracellular calcium via the sodium-calcium exchanger. This increased calcium enhances the force of cardiac contraction (positive inotropy). Additionally, digoxin increases vagal tone, which slows conduction through the AV node, making it useful for rate control in atrial fibrillation.
What are the side effects of digoxin?
The most serious side effect is cardiac arrhythmias, which can be life-threatening. Early signs of toxicity include gastrointestinal symptoms like nausea, vomiting, and anorexia. Neurological effects include confusion and characteristic visual disturbances such as yellow-green color vision (xanthopsia) or halos around lights. Bradycardia and AV block can also occur. Hypokalemia greatly increases the risk of digoxin toxicity and should be monitored closely.
Is digoxin a controlled substance?
No, digoxin is not a controlled substance under the DEA schedule. It is a prescription medication but does not have abuse potential. However, it does have a narrow therapeutic index and requires careful monitoring due to the risk of toxicity. Serum levels are often checked to ensure therapeutic dosing and to detect toxicity early.
What is the antidote for digoxin toxicity?
The specific antidote for severe digoxin toxicity is digoxin-specific antibody fragments, available as Digibind or DigiFab. These antibodies bind to digoxin molecules in the bloodstream, inactivating them and allowing renal excretion of the antibody-digoxin complex. This antidote is reserved for life-threatening toxicity such as severe arrhythmias, hyperkalemia greater than 5 mEq/L, or ingestion of potentially lethal doses. Supportive care includes correcting electrolyte abnormalities, especially potassium and magnesium.
Digoxin vs metoprolol for atrial fibrillation — what is the difference?
Both are used for rate control in atrial fibrillation, but they work differently. Digoxin increases vagal tone and is most effective at rest but less effective during exercise, making it better for sedentary patients or those with heart failure. Metoprolol, a beta-blocker, blocks sympathetic stimulation and provides better rate control during exercise and activity. Metoprolol is generally preferred as first-line for rate control in most patients, while digoxin is often reserved for those with concurrent heart failure or as adjunctive therapy.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: C01AA05
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.